Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJRU3A)

Drug Name

AMO-02 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Myotonic dystrophy	8C71.0	Phase 2/3	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycogen synthase kinase-3 beta (GSK-3B)	TTRSMW9	GSK3B_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Glycogen synthase kinase-3 beta (GSK-3B)	DTT	GSK3B	6.506	6.618	6.514	6.885

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Myotonic dystrophy

ICD Disease Classification

8C71.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glycogen synthase kinase-3 beta (GSK-3B)	DTT	GSK3B	1.26E-01	-0.23	-0.77

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03692312) Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)